Panbela Therapeutics, Inc. (PBLA)
- GlobeNewswire
Panbela Announces Issuance of New Patent in the US and Canada; Patent is for Claims of a Fixed Dose Combination of Eflornithine and Sulindac
Developed in collaboration with Sanofi.MINNEAPOLIS, May 06, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (OTCQB: PBLA), a clinical-stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with cancer, today announced an Issue Notification for the US continuation patent US 11,925,613 B2 and Canadian patent CA 3003149 titled “EFLORNITHINE AND SULINDAC, A FIXED DOSE COMBINATION FORMULATION”. These patents claim a novel composition of a fixed dose combi
- GlobeNewswire
Panbela to Host First Quarter 2024 Earnings Conference Call on May 15, 2024
MINNEAPOLIS, May 01, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (OTCQB: PBLA), (“Panbela”), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced that it will host a conference call on May 15, 2024, at 4:30 PM Eastern Time to discuss results for its first quarter ended March 31, 2024. Conference Call Information Toll Free: 877-545-0523International: 973-528-0016Participant Access Code: 234396Webcast Lin
- GlobeNewswire
Acceptance of Eflornithine (DFMO) Abstract for Oral Presentation at Digestive Disease Week
MINNEAPOLIS, April 30, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (OTCQB: PBLA), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with cancer today announced that an abstract for eflornithine, an inhibitor of polyamine synthesis, has been accepted for an oral presentation at the Digestive Disease Week (DDW) conference, which will be held May 18-21, 2024. The work reflects the Company’s on-going collaboration with Vanderbilt Univ
